Viewing Study NCT03614234


Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2026-03-02 @ 8:18 AM
Study NCT ID: NCT03614234
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-10-08
First Post: 2018-07-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Sponsor: Chiesi Farmaceutici S.p.A.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Fabry Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Glomerular filtration rate View
None Proteinuria View
None PRX-102 View
None pegunigalsidase alfa View
None Fabry disease View